Loading…

An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that has caused the recent coronavirus disease (COVID-19) global pandemic. The current approved COVID-19 vaccines have shown considerable efficiency against hospitalization and death. However, the continuation of the p...

Full description

Saved in:
Bibliographic Details
Published in:Progress in biophysics and molecular biology 2023-03, Vol.178, p.32-49
Main Authors: Bayani, Fatemeh, Hashkavaei, Negin Safaei, Arjmand, Sareh, Rezaei, Shokouh, Uskoković, Vuk, Alijanianzadeh, Mahdi, Uversky, Vladimir N., Ranaei Siadat, Seyed Omid, Mozaffari-Jovin, Sina, Sefidbakht, Yahya
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c479t-87e34a3c5dd696c120cae7d410213899745a5a1651469ebc9a384c74fd2e3bc3
cites cdi_FETCH-LOGICAL-c479t-87e34a3c5dd696c120cae7d410213899745a5a1651469ebc9a384c74fd2e3bc3
container_end_page 49
container_issue
container_start_page 32
container_title Progress in biophysics and molecular biology
container_volume 178
creator Bayani, Fatemeh
Hashkavaei, Negin Safaei
Arjmand, Sareh
Rezaei, Shokouh
Uskoković, Vuk
Alijanianzadeh, Mahdi
Uversky, Vladimir N.
Ranaei Siadat, Seyed Omid
Mozaffari-Jovin, Sina
Sefidbakht, Yahya
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that has caused the recent coronavirus disease (COVID-19) global pandemic. The current approved COVID-19 vaccines have shown considerable efficiency against hospitalization and death. However, the continuation of the pandemic for more than two years and the likelihood of new strain emergence despite the global rollout of vaccination highlight the immediate need for the development and improvement of vaccines. mRNA, viral vector, and inactivated virus vaccine platforms were the first members of the worldwide approved vaccine list. Subunit vaccines. which are vaccines based on synthetic peptides or recombinant proteins, have been used in lower numbers and limited countries. The unavoidable advantages of this platform, including safety and precise immune targeting, make it a promising vaccine with wider global use in the near future. This review article summarizes the current knowledge on different vaccine platforms, focusing on the subunit vaccines and their clinical trial advancements against COVID-19. [Display omitted]
doi_str_mv 10.1016/j.pbiomolbio.2023.02.004
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9938630</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0079610723000160</els_id><sourcerecordid>2778978504</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-87e34a3c5dd696c120cae7d410213899745a5a1651469ebc9a384c74fd2e3bc3</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxS0EokvLV0A-ckk6_pM4viCVLZRKlXqpOFWyHGfCepXEi-1sxbcn7baFnnqZOcx7b0bzI4QyKBmw-nRb7lofxjAsteTARQm8BJBvyIo1ShRMCf6WrACULmoG6oh8SGkLAJyp-j05EnUDTCq2IrdnEw17jHuPdzT0NG-Q7q1zfkK6G2zuQxwTzYG6MLY20_X1z8vzgml65_OGWtoHNycapgdjmtt58vkpIJ2Qd70dEn587Mfk5vu3m_WP4ur64nJ9dlU4qXQuGoVCWuGqrqt17RgHZ1F1ki3nikZrJStbWVZXTNYaW6etaKRTsu84itaJY_LlELub2xE7h1OOdjC76Ecb_5hgvXk5mfzG_Ap7o7VoagFLwOfHgBh-z5iyGX1yOAx2wjAnw5VqtGoqkIu0OUhdDClF7J_XMDD3bMzW_GNj7tkY4AYerJ_-P_PZ-ARjEXw9CHD51QIkmuQ8Tg47H9Fl0wX_-pa_xcGl9w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2778978504</pqid></control><display><type>article</type><title>An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines</title><source>Elsevier</source><creator>Bayani, Fatemeh ; Hashkavaei, Negin Safaei ; Arjmand, Sareh ; Rezaei, Shokouh ; Uskoković, Vuk ; Alijanianzadeh, Mahdi ; Uversky, Vladimir N. ; Ranaei Siadat, Seyed Omid ; Mozaffari-Jovin, Sina ; Sefidbakht, Yahya</creator><creatorcontrib>Bayani, Fatemeh ; Hashkavaei, Negin Safaei ; Arjmand, Sareh ; Rezaei, Shokouh ; Uskoković, Vuk ; Alijanianzadeh, Mahdi ; Uversky, Vladimir N. ; Ranaei Siadat, Seyed Omid ; Mozaffari-Jovin, Sina ; Sefidbakht, Yahya</creatorcontrib><description>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that has caused the recent coronavirus disease (COVID-19) global pandemic. The current approved COVID-19 vaccines have shown considerable efficiency against hospitalization and death. However, the continuation of the pandemic for more than two years and the likelihood of new strain emergence despite the global rollout of vaccination highlight the immediate need for the development and improvement of vaccines. mRNA, viral vector, and inactivated virus vaccine platforms were the first members of the worldwide approved vaccine list. Subunit vaccines. which are vaccines based on synthetic peptides or recombinant proteins, have been used in lower numbers and limited countries. The unavoidable advantages of this platform, including safety and precise immune targeting, make it a promising vaccine with wider global use in the near future. This review article summarizes the current knowledge on different vaccine platforms, focusing on the subunit vaccines and their clinical trial advancements against COVID-19. [Display omitted]</description><identifier>ISSN: 0079-6107</identifier><identifier>ISSN: 1873-1732</identifier><identifier>EISSN: 1873-1732</identifier><identifier>DOI: 10.1016/j.pbiomolbio.2023.02.004</identifier><identifier>PMID: 36801471</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>COVID-19 ; COVID-19 Vaccines ; Humans ; Knowledge ; Omicron ; SARS-CoV-2 ; Subunit vaccine ; Vaccine platforms ; Vaccines, Subunit</subject><ispartof>Progress in biophysics and molecular biology, 2023-03, Vol.178, p.32-49</ispartof><rights>2023 Elsevier Ltd</rights><rights>Copyright © 2023 Elsevier Ltd. All rights reserved.</rights><rights>2023 Elsevier Ltd. All rights reserved. 2023 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-87e34a3c5dd696c120cae7d410213899745a5a1651469ebc9a384c74fd2e3bc3</citedby><cites>FETCH-LOGICAL-c479t-87e34a3c5dd696c120cae7d410213899745a5a1651469ebc9a384c74fd2e3bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27898,27899</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36801471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bayani, Fatemeh</creatorcontrib><creatorcontrib>Hashkavaei, Negin Safaei</creatorcontrib><creatorcontrib>Arjmand, Sareh</creatorcontrib><creatorcontrib>Rezaei, Shokouh</creatorcontrib><creatorcontrib>Uskoković, Vuk</creatorcontrib><creatorcontrib>Alijanianzadeh, Mahdi</creatorcontrib><creatorcontrib>Uversky, Vladimir N.</creatorcontrib><creatorcontrib>Ranaei Siadat, Seyed Omid</creatorcontrib><creatorcontrib>Mozaffari-Jovin, Sina</creatorcontrib><creatorcontrib>Sefidbakht, Yahya</creatorcontrib><title>An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines</title><title>Progress in biophysics and molecular biology</title><addtitle>Prog Biophys Mol Biol</addtitle><description>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that has caused the recent coronavirus disease (COVID-19) global pandemic. The current approved COVID-19 vaccines have shown considerable efficiency against hospitalization and death. However, the continuation of the pandemic for more than two years and the likelihood of new strain emergence despite the global rollout of vaccination highlight the immediate need for the development and improvement of vaccines. mRNA, viral vector, and inactivated virus vaccine platforms were the first members of the worldwide approved vaccine list. Subunit vaccines. which are vaccines based on synthetic peptides or recombinant proteins, have been used in lower numbers and limited countries. The unavoidable advantages of this platform, including safety and precise immune targeting, make it a promising vaccine with wider global use in the near future. This review article summarizes the current knowledge on different vaccine platforms, focusing on the subunit vaccines and their clinical trial advancements against COVID-19. [Display omitted]</description><subject>COVID-19</subject><subject>COVID-19 Vaccines</subject><subject>Humans</subject><subject>Knowledge</subject><subject>Omicron</subject><subject>SARS-CoV-2</subject><subject>Subunit vaccine</subject><subject>Vaccine platforms</subject><subject>Vaccines, Subunit</subject><issn>0079-6107</issn><issn>1873-1732</issn><issn>1873-1732</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkU9v1DAQxS0EokvLV0A-ckk6_pM4viCVLZRKlXqpOFWyHGfCepXEi-1sxbcn7baFnnqZOcx7b0bzI4QyKBmw-nRb7lofxjAsteTARQm8BJBvyIo1ShRMCf6WrACULmoG6oh8SGkLAJyp-j05EnUDTCq2IrdnEw17jHuPdzT0NG-Q7q1zfkK6G2zuQxwTzYG6MLY20_X1z8vzgml65_OGWtoHNycapgdjmtt58vkpIJ2Qd70dEn587Mfk5vu3m_WP4ur64nJ9dlU4qXQuGoVCWuGqrqt17RgHZ1F1ki3nikZrJStbWVZXTNYaW6etaKRTsu84itaJY_LlELub2xE7h1OOdjC76Ecb_5hgvXk5mfzG_Ap7o7VoagFLwOfHgBh-z5iyGX1yOAx2wjAnw5VqtGoqkIu0OUhdDClF7J_XMDD3bMzW_GNj7tkY4AYerJ_-P_PZ-ARjEXw9CHD51QIkmuQ8Tg47H9Fl0wX_-pa_xcGl9w</recordid><startdate>20230301</startdate><enddate>20230301</enddate><creator>Bayani, Fatemeh</creator><creator>Hashkavaei, Negin Safaei</creator><creator>Arjmand, Sareh</creator><creator>Rezaei, Shokouh</creator><creator>Uskoković, Vuk</creator><creator>Alijanianzadeh, Mahdi</creator><creator>Uversky, Vladimir N.</creator><creator>Ranaei Siadat, Seyed Omid</creator><creator>Mozaffari-Jovin, Sina</creator><creator>Sefidbakht, Yahya</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230301</creationdate><title>An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines</title><author>Bayani, Fatemeh ; Hashkavaei, Negin Safaei ; Arjmand, Sareh ; Rezaei, Shokouh ; Uskoković, Vuk ; Alijanianzadeh, Mahdi ; Uversky, Vladimir N. ; Ranaei Siadat, Seyed Omid ; Mozaffari-Jovin, Sina ; Sefidbakht, Yahya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-87e34a3c5dd696c120cae7d410213899745a5a1651469ebc9a384c74fd2e3bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>COVID-19</topic><topic>COVID-19 Vaccines</topic><topic>Humans</topic><topic>Knowledge</topic><topic>Omicron</topic><topic>SARS-CoV-2</topic><topic>Subunit vaccine</topic><topic>Vaccine platforms</topic><topic>Vaccines, Subunit</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bayani, Fatemeh</creatorcontrib><creatorcontrib>Hashkavaei, Negin Safaei</creatorcontrib><creatorcontrib>Arjmand, Sareh</creatorcontrib><creatorcontrib>Rezaei, Shokouh</creatorcontrib><creatorcontrib>Uskoković, Vuk</creatorcontrib><creatorcontrib>Alijanianzadeh, Mahdi</creatorcontrib><creatorcontrib>Uversky, Vladimir N.</creatorcontrib><creatorcontrib>Ranaei Siadat, Seyed Omid</creatorcontrib><creatorcontrib>Mozaffari-Jovin, Sina</creatorcontrib><creatorcontrib>Sefidbakht, Yahya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Progress in biophysics and molecular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bayani, Fatemeh</au><au>Hashkavaei, Negin Safaei</au><au>Arjmand, Sareh</au><au>Rezaei, Shokouh</au><au>Uskoković, Vuk</au><au>Alijanianzadeh, Mahdi</au><au>Uversky, Vladimir N.</au><au>Ranaei Siadat, Seyed Omid</au><au>Mozaffari-Jovin, Sina</au><au>Sefidbakht, Yahya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines</atitle><jtitle>Progress in biophysics and molecular biology</jtitle><addtitle>Prog Biophys Mol Biol</addtitle><date>2023-03-01</date><risdate>2023</risdate><volume>178</volume><spage>32</spage><epage>49</epage><pages>32-49</pages><issn>0079-6107</issn><issn>1873-1732</issn><eissn>1873-1732</eissn><abstract>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that has caused the recent coronavirus disease (COVID-19) global pandemic. The current approved COVID-19 vaccines have shown considerable efficiency against hospitalization and death. However, the continuation of the pandemic for more than two years and the likelihood of new strain emergence despite the global rollout of vaccination highlight the immediate need for the development and improvement of vaccines. mRNA, viral vector, and inactivated virus vaccine platforms were the first members of the worldwide approved vaccine list. Subunit vaccines. which are vaccines based on synthetic peptides or recombinant proteins, have been used in lower numbers and limited countries. The unavoidable advantages of this platform, including safety and precise immune targeting, make it a promising vaccine with wider global use in the near future. This review article summarizes the current knowledge on different vaccine platforms, focusing on the subunit vaccines and their clinical trial advancements against COVID-19. [Display omitted]</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36801471</pmid><doi>10.1016/j.pbiomolbio.2023.02.004</doi><tpages>18</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0079-6107
ispartof Progress in biophysics and molecular biology, 2023-03, Vol.178, p.32-49
issn 0079-6107
1873-1732
1873-1732
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9938630
source Elsevier
subjects COVID-19
COVID-19 Vaccines
Humans
Knowledge
Omicron
SARS-CoV-2
Subunit vaccine
Vaccine platforms
Vaccines, Subunit
title An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-26T10%3A09%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20overview%20of%20the%20vaccine%20platforms%20to%20combat%20COVID-19%20with%20a%20focus%20on%20the%20subunit%20vaccines&rft.jtitle=Progress%20in%20biophysics%20and%20molecular%20biology&rft.au=Bayani,%20Fatemeh&rft.date=2023-03-01&rft.volume=178&rft.spage=32&rft.epage=49&rft.pages=32-49&rft.issn=0079-6107&rft.eissn=1873-1732&rft_id=info:doi/10.1016/j.pbiomolbio.2023.02.004&rft_dat=%3Cproquest_pubme%3E2778978504%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c479t-87e34a3c5dd696c120cae7d410213899745a5a1651469ebc9a384c74fd2e3bc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2778978504&rft_id=info:pmid/36801471&rfr_iscdi=true